The NSW Poisons and Therapeutic Goods Regulation 2008 (clause 48A) authorises appropriately trained pharmacists in NSW to administer the influenza vaccine, diphtheria-tetanus-pertussis (dTpa) vaccine, measles-mumps-rubella (MMR) vaccine and the COVID-19 AstraZeneca (ChAdOx1-S) vaccine to selected patients. The vaccine and conditions on the administration of the COVID-19 AstraZeneca (ChAdOx1-S) vaccine are approved by the Secretary NSW Health under clause 48A 1A(d) and 1B of the Regulation ,  Approval for COVID-19 AstraZeneca (ChAdOx1-S) vaccine. The NSW Pharmacist Vaccination Standards and more information is available on the NSW pharmacist vaccination program web page.

A registered pharmacist initiating and administering vaccines under his/her own authority must comply with the following three components of clause 48A of the NSW Poisons and Therapeutic Goods Regulation 2008 which prescribes rules for:

  • completing an accredited vaccination training course
  • conducting vaccinations under the NSW Pharmacist Vaccination Standards
  • recording each vaccination.

This provision applies to a pharmacist who holds general registration or provisional registration with the Pharmacy Board of Australia. A pharmacist with provisional registration who has completed an accredited vaccination training course may initiate and administer vaccines (other than the COVID-19 AstraZeneca (ChAdOx1-S) vaccine) only when under the supervision of a pharmacist who holds general registration, has completed an accredited vaccination training course and has determined the vaccination is appropriate for the particular person.

Current as at: Friday 16 July 2021
Contact page owner: Pharmaceutical Services